Last reviewed · How we verify
LA-EP2006
LA-EP2006 is a long-acting recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to and activating the erythropoietin receptor.
LA-EP2006 is a long-acting recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to and activating the erythropoietin receptor. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia.
At a glance
| Generic name | LA-EP2006 |
|---|---|
| Also known as | pegfilgrastim |
| Sponsor | Sandoz |
| Drug class | Erythropoietin receptor agonist |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
LA-EP2006 is designed as a biosimilar or long-acting EPO product that mimics the action of endogenous erythropoietin, binding to EPO receptors on erythroid progenitor cells in bone marrow to promote proliferation and differentiation into mature red blood cells. The long-acting formulation extends the dosing interval compared to conventional EPO products, improving patient convenience while maintaining hemoglobin levels in anemic patients.
Approved indications
- Anemia of chronic kidney disease
- Chemotherapy-induced anemia
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer (PHASE1, PHASE2)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (PHASE2)
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LA-EP2006 CI brief — competitive landscape report
- LA-EP2006 updates RSS · CI watch RSS
- Sandoz portfolio CI